Nilogen is dedicated to increasing efficiency and reducing risk in the oncology drug development process by creating 3D models of patient tumor biology, which are as accurate and informative as possible.
One of the most significant challenges facing the drug development industry is making the leap from drug discovery studies to the patient. Translating results from cell lines and animal models to clinical success is a process which still has an attrition rate of greater than 90%. The problem lies in how poorly most models capture the full breadth of complex biological processes that happen within the patient.
At Nilogen, we’ve developed the most clinically-relevant model of patient tumor biology and paired it with the latest analytical techniques, bioinformatics tools, and artificial intelligence algorithms to help translational scientists make better decisions about their candidate therapies. With this service offering, we are already helping companies uncover therapeutic candidates with the highest likelihood of success in the clinic, increasing the potential for success and reducing overall development costs.
Message from Nilogen CEO
Our work is dedicated to helping drug development organisations bring better drugs to market whilst reducing the burden of time and cost due to high attrition rates in the clinic. Ultimately it is all about how we, as a drug development community, improve the rate of success in treating cancer patients.
Nilogen was created with a specific mission – to significantly improve the rate of success for novel oncology therapies in the clinic through the use of our 3D-EXplore platform.
Sigrid M. Volko, Ph.D., CLP
President & CEO
Soner Altiok, M.D., Ph.D.
Chief Scientific Officer
Message from Nilogen CSO
In the last 10 years the percentage of cancer patients in the US eligible to receive immunotherapy has risen significantly, however, the number of patients who benefit from immunotherapy still remains low. We clearly have a long way to go to significantly impact the quality of life and survival rates for cancer patients.
We care as much about why patients do not respond to new treatments as the patients that do. A deeper understanding of the immunobiology of the tumor microenvironment is the key to potentially unlocking new paradigms in drug discovery and development. New targets drive novel discoveries and ultimately improved biomarkers and drugs for patients.
Nilogen was created with a specific mission – to significantly improve the rate of success for novel oncology therapies in the clinic. The development of novel cancer therapies is often challenged by discrepancies observed between preclinical and actual clinical studies, which is, at least in part, attributed to the lack of clinically relevant models for drug testing in the human tumor immune microenvironment.
Our work is dedicated to helping drug development organizations to bring better drugs to market whilst reducing the burden of time and cost due to high attrition rates in the clinic.
We envision a healthier future where our technology improves lives around the world by enabling the successful development of personalized cancer treatments and more affordable and accessible medicines.
At Nilogen, we constantly innovate, evolve, and challenge ourselves to develop novel solutions for oncology and immuno-oncology drug development by interrogating tumor microenvironment in our patient-derived tumoroid models through the application of cutting-edge technologies and advanced analytics.
Nilogen Oncosystems is led by a team of experienced and passionate individuals.
Join Nilogen’s dedicated team of researchers working for success in improving patient care.